CT ENTERPRISE (03839) announces a profit growth, expecting a net profit of approximately 32 million US dollars in 2025.
Zhengda Enterprise International (03839) announcement, due to the slowdown in the Chinese livestock industry, the demand for our animal health and drug products has also decreased since the third quarter of 2025. Nevertheless, the Group expects that comprehensive profit for the year 2025 will still experience growth. The Group expects to achieve a comprehensive profit attributable to shareholders of approximately USD 32 million for the year ended December 31, 2025, compared to USD 11.2 million for the year ended December 31, 2024. The increase in profit is mainly due to a significant increase in revenue, reflecting our successful implementation of key strategies in developing large customer sales.
CT ENTERPRISE (03839) announced that due to the slowdown in China's livestock industry, the demand for our animal health products has decreased since the third quarter of 2025. However, the Group still expects to achieve growth in comprehensive profit for the fiscal year 2025. The Group expects to achieve a comprehensive profit attributable to shareholders of approximately $32 million for the year ending December 31, 2025, compared to $11.2 million for the year ending December 31, 2024. The growth in profit is mainly due to a significant increase in revenue, reflecting the successful implementation of our key strategy to develop sales with large customers.
The Group expects that revenue for the quarter ending December 31, 2025 will remain at a similar level to the quarter ending September 30, 2025.
Related Articles
Shanghai Fosun Pharmaceutical (600196.SH): The application for the registration of metoprolol succinate injection has been approved.
SYNERTONE (01613): The rights issue received valid acceptance of approximately 9.71%.
Tianbo Intelligent's IPO listing on the Shanghai Stock Exchange has been queried, and its automotive thermostat revenue ranks third globally.
Shanghai Fosun Pharmaceutical (600196.SH): The application for the registration of metoprolol succinate injection has been approved.
SYNERTONE (01613): The rights issue received valid acceptance of approximately 9.71%.
Tianbo Intelligent's IPO listing on the Shanghai Stock Exchange has been queried, and its automotive thermostat revenue ranks third globally.
RECOMMEND
Paul Chan Says Hong Kong Has Licensed 11 Virtual Asset Exchanges, Stablecoin Licenses Expected Later This Year
22/01/2026
Ministry Of Finance And Other Departments Introduce Comprehensive Fiscal And Financial Policies To Boost Domestic Demand
22/01/2026
Capital Migration: Five Years On, An In‑Depth Analysis Of China’s 11 High‑Growth Venture Capital Tracks In 2025
22/01/2026
